John Smither

John William Smither is currently an Independent Director at Genelux Corp.
since 2023, an Independent Non-Executive Director at NewAmsterdam Pharma Co. NV since 2023, a Director at eFFECTOR Therapeutics Operations, Inc. since 2018, and a Member of The American Institute of Certified Public Accountants, Financial Executives International, and California Society of Certified Public Accountants.
Mr. Smither is also set to be Chief Financial Officer at MBX Biosciences, Inc. starting in 2026.
Former positions include Independent Director at Achaogen, Inc. from 2013 to 2020, Independent Director at Principia Biopharma, Inc. in 2019, Director at Dompe Biotec SpA, Independent Director at eFFECTOR Therapeutics, Inc. from 2018 to 2023, Independent Director at Applied Molecular Transport, Inc. from 2022 to 2023, Vice President-Finance & Administration at Amgen, Inc. from 2001 to 2004, Chief Financial Officer at Kythera Biopharmaceuticals LLC from 2007 to 2015, Audit Partner at Ernst & Young LLP (Missouri), Chief Financial Officer at Amgen Europe BV from 2001 to 2004, Chief Financial Officer at Kite Pharma, Inc. from 2017 to 2018, Chief Financial Officer at Unity Biotechnology, Inc. from 2016 to 2017, Chief Financial Officer at Sienna Biopharmaceuticals, Inc. from 2016 to 2017 and again from 2018 to 2019, Chief Financial Officer at Arcutis Biotherapeutics, Inc. from 2019 to 2021 and from 2023 to 2024.
Education includes undergraduate studies at California State University-Los Angeles.